From: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
 | All grade (grade 3-4), % of patients | |
---|---|---|
Adverse event | Imatinib 400 mg QD | Dasatinib 100 mg QD |
Nonhematologic | Â | Â |
   Nausea | 20 (0) | 8 (0) |
   Diarrhea | 17 (1) | 17 (< 1) |
   Vomiting | 10 (0) | 5 (0) |
   Rash | 17 (1) | 11 (0) |
   Headache | 10 (0) | 12 (0) |
   Fatigue | 10 (0) | 8 (< 1) |
   Musculoskeletal pain | 14 (< 1) | 11 (0) |
   Muscle inflammation | 17 (< 1) | 4 (0) |
   Fluid retention | 42 (1) | 19 (1) |
Superficial edema | 36 (< 1) | 9 (0) |
Pleural effusion | 0 (0) | 10 (0) |
Other | 8 (< 1) | 5 (1) |
Hematologic | Â | Â |
   Neutropenia | 58 (20) | 65 (21) |
   Thrombocytopenia | 62 (10) | 70 (19) |
   Anemia | 84 (7) | 90 (10) |
Biochemical abnormalities | Â | Â |
   Elevated AST | NL (1) | NL (< 1) |
   Elevated ALT | NL (1) | NL (< 1) |
   Elevated bilirubin | NL (0) | NL (1) |
   Elevated lipase | NL (0) | NL (0) |
   Hyperglycemia | NL (0) | NL (0) |
   Elevated amylase | NL (0) | NL (0) |
   Decreased phosphorus | NL (21) | NL (4) |